Results 61 to 70 of about 3,573 (200)

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study

Pain and Therapy
Introduction To provide real-world insights into migraine patient population in Germany treated with erenumab, focusing on the prescription patterns and reasons for the initial dosage choice.
Charly Gaul, Astrid Gendolla, Dagny Holle, Hartmut Göbel, Mirja Koch, Caroline Baufeld, Cordula Weiss   +6 more
doaj   +1 more source

Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation

The Journal of Headache and Pain, 2022
Background Calcitonin gene-related peptide (CGRP) inhibitors have been developed as options for treatment of chronic and episodic migraine. We present our experience of the use of erenumab in a tertiary headache centre.
Michael Lowe, Lesley Murray, Alok Tyagi, George Gorrie, Sarah Miller, Krishna Dani, the NHS Greater Glasgow and Clyde Headache Service   +6 more
doaj   +1 more source

Both perimenstrual and nonperimenstrual migraine days respond to anti-calcitonin gene-related peptide (receptor) antibodies [PDF]

, 2023
Background and purpose: Anti-calcitonin gene-related peptide (CGRP) (receptor) antibodies effectively reduce overall migraine attack frequency, but whether there are differences in effect between perimenstrual and nonperimenstrual migraine days has not ...
de Vries Lentsch, Simone, le Cessie, Saskia, MaassenVanDenBrink, Antoinette, Terwindt, Gisela M., van der Arend, Britt W.H., Verhagen, Iris E.   +5 more
core   +3 more sources

Delayed urticaria during treatment with anti‐CGRP monoclonal antibodies in migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To characterize clinical presentation and management of urticaria associated with calcitonin gene‐related peptide (CGRP) ‐targeting monoclonal antibodies (mAbs) for migraine prophylaxis. Background CGRP‐targeting mAbs are effective in migraine prophylaxis, but have been associated with hypersensitivity reactions, including urticaria.
Christoph T. Berger, Federico Burguet Villena, Severin B. Vogt, Lukas Heydrich, Karin Hartmann, Athina Papadopoulou   +5 more
wiley   +1 more source

Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO‐CGRP study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aimed to evaluate demographic characteristics, treatment effectiveness, and safety outcomes in patients with migraine undergoing anti‐calcitonin gene‐related peptide (CGRP) treatments regarding the presence of autoimmune diseases. Background CGRP has an important role in migraine pathophysiology through neuronal modulation
María Clara García‐Castillo, Álvaro Sierra‐Mencía, Edoardo Caronna, Daniel Toledo‐Alfocea, Alex Jaimes, Sarai Urtiaga, Javier Casas‐Limón, Albert Muñoz‐Vendrell, Sonia Santos‐Lasaosa, Valvanuz García Martín, Guillermo Martín Ávila, Marcos Polanco, Maria Dolores Villar‐Martínez, Cristina Trevino‐Peinado, Laura Rubio‐Flores, Antonio Sánchez‐Soblechero, Leonardo Portocarrero Sánchez, Elisa Luque‐Buzo, Alberto Lozano‐Ros, Ana Beatriz Gago‐Veiga, Javier Díaz‐De‐Terán, Andrea Recio García, Javiera Canales Rodríguez, Andrea Gómez García, Marta González Salaices, Sergio Campoy, Ane Mínguez‐Olaondo, Stefania Maniataki, Vicente González‐Quintanilla, Jesús Porta‐Etessam, María‐Luz Cuadrado, Ángel Luis Guerrero Peral, Patricia Pozo‐Rosich, Jaime Rodríguez‐Vico, Mariano Huerta‐Villanueva, Julio Pascual, Peter J. Goadsby, Alicia Gonzalez‐Martinez   +37 more
wiley   +1 more source

Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial

BMJ Open, 2023
Objectives To evaluate the 1-year efficacy and safety of once-monthly erenumab 70 mg following a 24-week double-blind treatment period (DBTP) of a phase III randomised study of Japanese patients with episodic migraine (EM) or chronic migraine (CM).Design
Koichi Hirata, Fumihiko Sakai, Miki Hasebe, Takao Takeshima, Yotaro Numachi, Ryuji Yoshida, Reija Koukakis, Daishi Yui, Gabriel Paiva da Silva Lima, Sunfa Cheng   +9 more
doaj   +1 more source

Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). [PDF]

, 2019
BACKGROUND: Patients with high-frequency episodic migraine (HFEM) have a greater disease burden than those with low-frequency episodic migraine (LFEM).
Day, Katie A., Lipsius, Sarah, Silberstein, Stephen D., Stauffer, Virginia L., Wilson, Maria-Carmen   +4 more
core   +1 more source

Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies [PDF]

, 2021
Background Migraine preventive treatment with CGRP(-receptor) monoclonal antibodies (mAbs) has a positive effect on patients' health-related quality of life (HRQoL).
Mecklenburg, Jasper, Neeb, Lars, Overeem, Lucas Hendrik, Raffaelli, Bianca, Reuter, Uwe, Siebert, Anke, Steinicke, Maureen, Terhart, Maria   +7 more
core   +1 more source

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To compare the 3‐month effectiveness of galcanezumab with select traditional oral migraine preventive (TOMP) medications recommended by scientific societies (TOMP efficacy subset) and with the most frequently used individual TOMP medications.
Shivang Joshi, Cristina Tassorelli, Manjit Matharu, Taoufik Alsaadi, Carlos Vallarino, Lars Viktrup, Maurice Vincent, Rebecca L. Robinson   +7 more
wiley   +1 more source